RECENT ADVANCES IN OVARIAN CANCER
The program will examine hereditary ovarian cancer including how genetic testing is being utilized to identify high-risk women and to tailor therapy for women with ovarian cancer, new surgical and chemotherapeutic options for the initial management of ovarian cancer, and novel therapeutic approaches for women with recurrent ovarian cancer. The target audience includes oncologists, obstetricians/gynecologists, and primary care providers.
At the conclusion of this activity, participants should be able to:
Discuss the advances and potential limitations of genomic medicine in providing early detection, risk assessment, treatment guidance to women at high risk for developing hereditary breast and ovarian cancer.
Discuss the treatment of recurrent epithelial ovarian cancer for platinum sensitive and platinum resistant patients, including new targeted therapies.